Abstract: The present invention provides biological molecules for use in detecting, identifying and/or removing microbes and microbial components; diagnostic, therapeutic and filtration devices comprising the biological molecules; and systems and methods for treating fluids using the biological molecules and devices of the invention.

Abstract: Compositions, systems and methods are provided for the treatment of subcutaneous brown or beige fat or visceral brown or beige fat, wherein the compositions comprise a cold solution comprising liquid water and/or ice particles, and optionally one or more additives and/or pharmacologic agents. The treatment of subcutaneous or visceral brown or beige fat provides activation of brown adipocytes, proliferation of brown adipocytes, increased volume of brown adipocytes, differentiation of precursors into beige and/or brown adipocytes, activation of beige adipocytes, stimulation of beige adipocytes and/or cryolipolysis of white adipocytes. The methods of treatment result in increased metabolic health, weight loss, and improved health.

Abstract: The present invention provides biological molecules for use in detecting, identifying and/or removing microbes and microbial components; diagnostic, therapeutic and filtration devices comprising the biological molecules; and systems and methods for treating fluids using the biological molecules and devices of the invention.

Abstract: The present invention provides a cold solution and method for treating obstructive sleep apnea. The cold solution can comprise liquid and/or solid ice particles. In one embodiment, the method comprises delivering a cold solution to target tissue where the target tissue can be fat tissue located in one or more of an airway, a neck, a thorax, a diaphragm, a face, or an abdomen.

Abstract: A substantially solid solution is provided, which includes water and optionally one or more additives, wherein about 71% to about 100% of the water by volume is in a solid state. The substantially solid solution may be administered to a subcutaneous fat layer of a subject, in order to reduce or remove adipocytes through freezing. The substantially solid solution may be generated in a mold, or at a point of delivery, and may be administered by any suitable device or administered directly to a treatment site via an incision.

Abstract: The present invention provides a cold solution and method for inducing therapeutic hypothermia. The cold solution can comprise liquid and/or solid ice particles.

Abstract: A slurry is injected into a subject at a treatment site selected from the group consisting of (i) a deep subcutaneous fat layer, (ii) a superficial subcutaneous fat layer, and (iii) the deep subcutaneous fat layer and the superficial subcutaneous fat layer. Fat cells in the selected treatment site are ablated by the slurry. For example, the slurry is injected into (i) the deep subcutaneous fat layer only, (ii) the superficial subcutaneous fat layer only, (iii) the deep subcutaneous fat layer followed by the superficial subcutaneous fat layer, (iv) the superficial subcutaneous fat layer followed by the deep subcutaneous fat layer, or (v) the deep subcutaneous fat layer and the superficial subcutaneous fat layer simultaneously.

Abstract: Methods and systems for generating sterile slurry are provided. The slurry may be injected into subcutaneous fat of a subject to facilitate weight reduction or improve cosmetic appearances. Systems for generating a slurry comprise a repository for receiving a solution, a generator for generating the slurry from the solution, and a port for transferring the slurry from the system. Methods for generating a slurry comprise receiving a solution in a slurry generator, and generating slurry from the solution, wherein the slurry comprises ice particles capable of flowing through a cannula. Systems include continuous flow systems, agitated systems, and hybrid continuous flow and agitation systems.

Abstract: Systems and methods for generating slurry for injection are provided. Systems comprise a container and a device. The container comprises a solution for administration via an injection needle of a predetermined size. The device is capable of receiving the solution and producing a slurry having ice particles capable of flowing through the injection needle. Methods comprise selecting a container having the solution, receiving the solution in the device, and producing, in the device, the slurry having ice particles capable of flowing through the injection needle.

Abstract: In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.

Abstract: In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.

Abstract: A device comprising a single closed loop of elastic filament configurable between (i) a first configuration for movement along a blood vessel; and (ii) a second configuration for lodging within a blood vessel, the second configuration providing a single flow-restricting face sized and configured to cover the mouth of the aneurysm and obstruct blood flow to the aneurysm while permitting substantially normal blood flow through the blood vessel, with the degree of obstruction at the mouth of the aneurysm being such that the aneurysm thromboses when the face is positioned over the aneurysm, the flow-restricting face comprising a plurality of lengths of the closed loop of filament disposed in close proximity to one another in a switchback configuration, and at least one leg for holding the flow-restricting face adjacent the mouth of the aneurysm, the leg configured so as to maintain substantially normal blood flow through the blood vessel.

Abstract: In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.

Abstract: A locking assembly is provided to simply and effectively prevent any unintentional adjustment of the adjustable valve mechanism in a fluid flow control device, without compromising the function of the device. The locking assembly generally includes at least one gripping arm for frictionally engaging at least a portion of the adjustable valve mechanism, and an actuating mechanism for controlling the deployment and release of the gripping arm. The locking assembly prevents unintentional adjustments that can adversely affect the pressure settings of the fluid flow control device. In particular, the locking assembly prevents unintentional adjustment, such as may be caused by the presence of a strong external magnetic field. The locking assembly can be easily disengaged, such as through the application or removal of an external mechanical force, to allow a clinician to adjust the pressure settings of the fluid flow control device as necessary.

Abstract: An acoustic monitoring system that is able to verify the success or failure of the positional adjustment of a valve without the need for additional energy during non-invasive reprogramming is provided. The acoustic monitoring system includes a programmer for generating a sequence of commands to adjust the valve mechanism, and for receiving acoustic signals for analysis, a transmitter to implement the command and adjust the valve, and a sensor for detecting an acoustic signal generated from the valve during execution of the commands. A method for using the acoustic monitoring system is also provided.

Abstract: A locking assembly is provided to simply and effectively prevent any unintentional adjustment of the adjustable valve mechanism in a fluid flow control device, without compromising the function of the device. The locking assembly generally includes at least one gripping arm for frictionally engaging at least a portion of the adjustable valve mechanism, and an actuating mechanism for controlling the deployment and release of the gripping arm. The locking assembly prevents unintentional adjustments that can adversely affect the pressure settings of the fluid flow control device. In particular, the locking assembly prevents unintentional adjustment, such as may be caused by the presence of a strong external magnetic field. The locking assembly can be easily disengaged, such as through the application or removal of an external mechanical force, to allow a clinician to adjust the pressure settings of the fluid flow control device as necessary.

Abstract: A locking assembly is provided to simply and effectively prevent any unintentional adjustment of the adjustable valve mechanism in a fluid flow control device, without compromising the function of the device. The locking assembly generally includes at least one gripping arm for frictionally engaging at least a portion of the adjustable valve mechanism, and an actuating mechanism for controlling the deployment and release of the gripping arm. The locking assembly prevents unintentional adjustments that can adversely affect the pressure settings of the fluid flow control device. In particular, the locking assembly prevents unintentional adjustment, such as may be caused by the presence of a strong external magnetic field. The locking assembly can be easily disengaged, such as through the application or removal of an external mechanical force, to allow a clinician to adjust the pressure settings of the fluid flow control device as necessary.

Abstract: A shunt has a housing and a base. The base has a first set of electrodes extending across the base. A catheter is connected to the housing. The catheter has a longitudinal length, a proximal end, and a distal end. The catheter has a second set of electrodes extending along the longitudinal length of the catheter. At least two of the electrodes of said first set are electrically connected to two of the electrodes of the second set. The housing including a self sealing, needle penetrable outer housing wall. The system includes a probe assembly that is selectively penetratable through an outer housing wall.

Abstract: A package for a drug-device combination product includes an outer package including a first gas impermeable sheet and a second gas impermeable sheet hermetically sealed there to on three sides. A gas permeable header is attached to an unsealed side of the first sheet and sealed to the second sheet on two sides. The first and second gas impermeable sheets and the header form an interior and an opening communicating with the interior. A gas permeable inner package is disposed within the outer package. A product is sealed within the inner package. The inner package is placed within the outer package and a top end of the header is sealed to the second sheet. The outer package is then sealed by sealing the first gas impermeable sheet to the second gas impermeable sheet at a seal point below the point where the header attaches to the first sheet.

Abstract: A package for a drug-device combination product includes an outer package including a first gas impermeable sheet and a second gas impermeable sheet hermetically sealed there to on three sides. A gas permeable header is attached to an unsealed side of the first sheet and sealed to the second sheet on two sides. The first and second gas impermeable sheets and the header form an interior and an opening communicating with the interior. A gas permeable inner package is disposed within the outer package. A product is sealed within the inner package. The inner package is placed within the outer package and a top end of the header is sealed to the second sheet. The outer package is then sealed by sealing the first gas impermeable sheet to the second gas impermeable sheet at a seal point below the point where the header attaches to the first sheet.